The U.S. Department of Health and Human Services (HHS) announced a new rule on Tuesday restricting Medicaid and the Children’s Health Insurance Program (CHIP) from covering puberty blockers, hormone therapy, and surgeries for the treatment of gender dysphoria in minors. The rule does not ban these procedures but prohibits federal funding for them under the affected programs.
Assistant Secretary of Health Admiral Brian Christine, a urologist overseeing public health programs within HHS, stated that the decision prioritizes mental health counseling over medical interventions for gender dysphoria in children. Christine, who leads the U.S. Public Health Service Commissioned Corps, argued that the majority of minors diagnosed with gender dysphoria do not require medical transition if provided with appropriate support.
The rule applies to Medicaid and CHIP, which collectively provide health coverage for millions of low-income children in the U.S. HHS officials described the treatments as experimental and highlighted potential long-term, irreversible risks, including life-altering complications from cross-sex hormones and surgeries. The announcement follows a broader policy shift under the Trump administration aimed at restricting access to what officials characterize as sex-rejecting procedures for minors.
Christine emphasized that the rule targets financial incentives behind pediatric gender treatments, stating that the procedures should not be funded through taxpayer-supported programs. He cited concerns over the rapid increase in diagnoses of gender dysphoria among minors, which he described as a social contagion rather than a purely medical phenomenon. According to Christine, competent counseling is the preferred approach for most children experiencing gender dysphoria.
The policy change does not affect private insurance coverage or adult gender-affirming care. HHS officials confirmed that the rule will take effect immediately, though implementation timelines for state Medicaid programs may vary. The announcement has drawn both support from conservative groups and criticism from LGBTQ+ advocacy organizations, which argue that the restrictions limit access to necessary medical care for transgender youth.
Critics of the rule contend that it denies medically necessary care to a vulnerable population, citing guidelines from major medical associations—including the American Academy of Pediatrics—that endorse gender-affirming care for minors in certain cases. Supporters of the policy, however, applaud the move as a protection against irreversible medical harm and an overreach of federal funding for controversial treatments.
HHS has not provided a comprehensive estimate of how many minors currently receive these treatments under Medicaid or CHIP. The rule’s implementation will be monitored by state health departments, which will determine compliance and enforcement mechanisms. The policy reflects a broader debate over the appropriate medical and ethical standards for treating gender dysphoria in children, with ongoing legal and legislative challenges expected in the coming months.